Investigation on molecular markers for assessment of biological activity in prostate cancer

前列腺癌生物活性评估分子标志物的研究

• 批准号: 05807146
• 负责人: EGAWA Shin
• 金额: $ 1.22万
• 依托单位: Kitasato University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1995
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05807146/
• 关键词: prostate cancer; biological significance; genomic instability; DNA ploidy; Transforming growth factor beta 1; 進行因子; 分子生物学的マーカー; DNA-ploidy; microsatellite instability; 人種差; 遺伝子; 迫行性病変

The frequent detection of clinically silent prostate cancer in autopsy studies suggests a benign natural history of the disease in some men, but more aggressive and potentially lethal cancers in others. In order to determine molecular markers for progression, genomic instability of microsatellites repeats, DNA ploidy status and serum transforming growth factor beta 1 levels were investigated for their usefulness to predict more aggressive phenotype. Sixty-six patients with prostate adenocarcinoma were screened for somatic instability at 8 microsatellite marker loci on 5 chromosomes. Genomic instability was detected in 13 (19.7%) patients. Extraglandular spread was found to show significant association with somatic instability after controlling for other clinicopathological variables. It was suggested that polymerase chain reaction based microsatellite instability assay may serve as a useful molecular prognostic marker in prostate cancer. DNA ploidy of each focus of a cancer in 70 radical prostatectomy specimens was determined by nuclear image analysis. Of the 103 individual cancers, 64 (62%) were nondiploid. DNA ploidy was weakly correlated with increase in tumor volume but not tumor grade. The relationship between DNA ploidy and extraprostatic spread was not statistically significant. Serum levels of transforming growth factor beta 1 were correlated with tumor grade and stage in 260 patients with prostate cancer. There was no correlation seen between these variables

在尸检研究中经常发现临床上无症状的前列腺癌，这表明某些男性的疾病有良性的自然史，但在其他人中则是更具侵略性和潜在致命性的癌症。为了确定进展的分子标志物，研究了微卫星重复序列的基因组不稳定性、DNA倍性状态和血清转化生长因子β 1水平对预测更具侵袭性表型的有用性。对66例前列腺癌患者进行了5条染色体上8个微卫星标记位点的体细胞不稳定性筛查。13例（19.7%）患者检测到基因组不稳定。在控制了其他临床病理变量后，发现腺体外扩散与体细胞不稳定性有显著相关性。提示聚合酶链反应微卫星不稳定性检测可作为前列腺癌预后的一个有用的分子指标。应用核图像分析技术对70例乳腺癌根治术标本中每个癌灶的DNA倍体进行了测定。在103例个体癌症中，64例（62%）为非二倍体。DNA倍体与肿瘤体积的增加呈弱相关，但与肿瘤分级无关。DNA倍体与前列腺外播散的关系无统计学意义。260例前列腺癌患者血清转化生长因子β 1水平与肿瘤分级和分期相关。这些变量之间没有相关性

项目成果

頴川 晋,他: "直腸診,画像診断では検出できない前立腺癌(Tlc癌)の臨床病理学的検討" Jpn.Urol.(in press).

Susumu Tokawa 等人：“无法通过直肠检查或图像诊断检测到的前列腺癌（TLC 癌症）的临床病理学研究”Jpn。

Toyoaki Uchida, Shin Egawa,et al.: "INFREQUENT IN VOLVEMENT OF p53 MUTATIONS ANDLOSS OF HETEROZYGOSITY OF 17p IN THE TUMORIGENESIS OF RENAL CELL CARCINOMA" THE JOURNAL OF UROLOGY. 150. 1298-1301 (1993)

Toyoaki Uchida、Shin Egawa 等人：“肾细胞癌肿瘤发生中 p53 突变的罕见发生和 17p 杂合性的丧失”《泌尿学杂志》。

Shin Egawa et al.: "Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer" Urology. 47(in press). (1996)

Shin Ekawa 等人：“脱氧核糖核酸倍性状态作为临床可切除前列腺癌病理分期预测的基础”泌尿学。

頴川 晋,他: "Stage Tlc前立腺癌の臨床的重要性。" 泌尿器外科. 8. 93-101 (1995)

Susumu Tokawa 等人：“TLC 前列腺癌的临床重要性”，8. 93-101 (1995)。

Shin Egawa et al.: "Deoxyribonucleic acid ploidy ststus as no basis for pathologic stage prediction in clinically resectable prostate cancer" Urology. 47 (in press). (1996)

Shin Ekawa 等人：“脱氧核糖核酸倍性状态作为临床可切除前列腺癌病理分期预测的基础”泌尿学。